Immunotherapy
Perspectives
ESMO guidelines provide ‘clear blueprint’ for managing immunotherapy toxicities
‘I’d like to talk to you today about something specific and generic around guidelines.’
Latest News
Adverse events linked to better survival with ICIs in melanoma
“We feel these findings will help clinicians in discussions with patients and in clinical decision-making after adverse events develop,” one of...
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
From the Journals
Cell-killing cancer therapy treats lupus successfully
“Our data reveal unexpected insights for a role of CAR T cells in nonmalignant diseases that could provide new opportunities for the treatment of...
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Acetaminophen linked to diminished response to immunotherapy in cancer
“Commonly used medications may have a larger impact on the efficacy and toxicity of immune checkpoint blockade than historically seen with...
From the Journals
Age, skin cancer risks for ICI-induced bullous pemphigoid identified
“It’s harder to understand why a presumably antibody-mediated side effect would be more likely to have that cross-reactivity where the tumor...
From the Journals
New injectable gel can deliver immune cells directly to cancer tumors
The gel “is a really exciting step forward because it can change the delivery of these cells and expand this kind of treatment to other cancers...
Latest News
Adverse skin effects of cancer immunotherapy reviewed
“The desirable, immune-mediated oncologic response is often achieved at the cost of immune-related adverse events (irAEs) that may potentially...
From the Journals
Women at higher risk of serious adverse events from cancer therapy
As cancer treatment becomes increasingly individualized, “sex may be an important consideration.”
From the Journals
Review eyes nail unit toxicities secondary to targeted cancer therapy
Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies....